

IPR and Innovation

1. [Is global pharma industry investing enough in pain killer research?](#) – Business Standard
2. [Roche CEO attacks Britain's 'stupid' cancer drug system](#) - Reuters

Access to Healthcare

1. [Addressing gaps in national vision of "Health for All"](#) – Deccan Herald

Others

1. [GSK Pharma begins work to set up Rs 1,000-cr manufacturing unit in Karnataka](#) – The Economic Times
-

IPR and Innovation

1. [Is global pharma industry investing enough in pain killer research?](#) – Business Standard
Funding is difficult to come by for pain killer research since challenges of data collection for clinical trials is high as compared to any other therapeutic area. The dimension of physical pain for human beings range from a minor back pain to low back pain, back pain, osteoarthritis/rheumatoid arthritis, joint pain, muscle pain, neuropathic pain, Phantom Limb Pain, Stump Pain, brachial plexus avulsion, differentiation pain, facial pain, complex regional pain syndrome, etc. In most diseases, painkillers are a part of every doctor's prescription. As a practice, generic versions of existing and available pain killers are prescribed by doctors for the masses. Newer drugs in this area like the 'Cox' inhibitors perished and made drastic impact on the sales of companies which sold those leaving companies and doctors to resort to the traditional [diclofenac](#) and combinations.
2. [Roche CEO attacks Britain's 'stupid' cancer drug system](#) – Reuters
Roche Chief Executive Severin Schwan criticized Britain's health system on Tuesday after two of the company's cancer drugs were dropped from use, calling it a "stupid" way to control costs that could jeopardize research in the country. He also criticized India, an emerging economic powerhouse, for not doing more to increase its spending on healthcare. The Roche boss had harsh words for India, too, saying the country was not spending enough as a percentage of its gross domestic product on healthcare, estimating it at only about 1 percent to 2 percent. He said that salvos targeting drug companies over the high cost of medicines in developing countries were distractions from this more important issue.

Access to Healthcare

1. [Addressing gaps in national vision of "Health for All"](#) – Deccan Herald
Now that the Millennium Development Goals (MDGs) are nearing their end, the governments are confronting the "unfinished" agenda of development. This will be tackled by a new set of goals, the Sustainable Development Goals (SDGs), to be launched by the UN secretary general at the United Nations General Assembly later this month. At this time, Prime Minister Narendra Modi will present the national strategy to meet the SDG goals and targets – a five-pronged action plan focused on financing, accountability, community engagement, advocacy, and research and innovation- from 2016 to 2030.

Others

1. [GSK Pharma begins work to set up Rs 1,000-cr manufacturing unit in Karnataka](#) – The Economic Times
GlaxoSmithKline Pharmaceuticals BSE -0.70 % today began work for setting up a Rs 1,000 crore pharmaceutical manufacturing unit in Karnataka. He added, "We fully support the Government in their efforts to increase access to affordable medicines to improve healthcare and we are very excited to begin work on what will become our largest manufacturing facility in India."